The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Merck has filed its immunotherapy drug Keytruda for use in lung cancer patients, and has pinpointed its benefits for patients who carry a special biomarker. New data has confirmed that the drug is ...

The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy ... This year’s 19th Annual New York Lung Cancers Symposium® will focus on treatment strategies in early-stage lung ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...